Loading
Rgenta Therapeutics makes tablet medicines that act on a gene's RNA message rather than its protein; its lead drug switches off MYB, the driver of adenoid cystic carcinoma, a rare cancer of the salivary glands.
Rgenta Therapeutics, Inc., of Woburn, Massachusetts, develops oral small-molecule RNA-targeting medicines: small molecule glues that stabilise the interaction between a target RNA and the splicing machinery so that the target RNA is degraded. Its lead programme RGT-61159 inhibits production of the oncogenic transcription factor MYB and is in a phase 1a/b trial in relapsed or refractory adenoid cystic carcinoma and colorectal cancer (NCT06462183); it received FDA orphan drug designation for adenoid cystic carcinoma in September 2025, and in October 2026 the company announced an end-of-phase 2 meeting with the FDA and alignment on a phase 3 design. Preclinical work extends RGT-61159 to acute myeloid leukaemia, and the company has a CNS programme and an RSwitch gene-regulation technology. In January 2024 it joined the Leukemia & Lymphoma Society Therapy Acceleration Program, which provided strategic funding. Its first registered cancer trial, NCT06462183, was posted on ClinicalTrials.gov in June 2024.
| Round | Year | Amount | Source |
|---|---|---|---|
| Strategic investment (LLS TAP) · Amount not stated | 2024 | undisclosed | prnewswire.com |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Shares Leukemia & Lymphoma Society Therapy Acceleration Program, Acute myeloid leukaemia.
Shares Leukemia & Lymphoma Society Therapy Acceleration Program, Acute myeloid leukaemia.
Shares Molecular glue discovery platforms, Colorectal cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/